Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Boceprevir (INN, trade name Victrelis) is a protease inhibitor used to treat hepatitis caused by hepatitis C virus (HCV) genotype 1. It binds to the HCV nonstructural protein 3 active site.
Clinical trials & Overview
Explore the main themes, entities and connections around Boceprevir. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
patients weeks peginterferon ribavirin citation needed plus therapy group received hcv trial 44 genotype victrelis study alfa-2b three peginterferon-ribavirin hepatitis
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Boceprevir | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Boceprevir | AHFS/Drugs.com | Consumer Drug Information | 1.00 | infobox |
| Boceprevir | ATC code | J05AP03 (WHO) | 1.00 | infobox |
| Boceprevir | CAS Number | 394730-60-0 Y | 1.00 | infobox |
| Boceprevir | ChEMBL | ChEMBL218394 Y | 1.00 | infobox |
| Boceprevir | ChemSpider | 8499830 Y | 1.00 | infobox |
| Boceprevir | CompTox Dashboard (EPA) | DTXSID30960103 | 1.00 | infobox |
| Boceprevir | DrugBank | DB08873 Y | 1.00 | infobox |
| Boceprevir | ECHA InfoCard | 100.226.246 | 1.00 | infobox |
| Boceprevir | Elimination half-life | 3.4 hours | 1.00 | infobox |
| Boceprevir | Formula | C27H45N5O5 | 1.00 | infobox |
| Boceprevir | IUPHAR/BPS | 7876 | 1.00 | infobox |
| Boceprevir | KEGG | D08876 Y | 1.00 | infobox |
| Boceprevir | Legal status | US: ℞-only | 1.00 | infobox |
| Boceprevir | License data | EU EMA: by INN | 1.00 | infobox |
| Boceprevir | License data | US FDA: Boceprevir | 1.00 | infobox |
| Boceprevir | MedlinePlus | a611039 | 1.00 | infobox |
| Boceprevir | Molar mass | 519.687 g·mol−1 | 1.00 | infobox |
| Boceprevir | NIAID ChemDB | 398493 | 1.00 | infobox |
| Boceprevir | Protein binding | 75% | 1.00 | infobox |
| Boceprevir | PubChem CID | 10324367 | 1.00 | infobox |
| Boceprevir | Routes of administration | Oral | 1.00 | infobox |
| Boceprevir | Trade names | Victrelis | 1.00 | infobox |
| Boceprevir | UNII | 89BT58KELH | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.